Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study

BACKGROUND: Though a single nonmedical switch from the originator infliximab (IFX) to a biosimilar is considered effective and safe for most patients with inflammatory bowel disease (IBD), very limited data are available on multiple successive switches. METHODS: We performed a prospective multicente...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanzel, Jurij, Jansen, Jeroen M, ter Steege, Rinze W F, Gecse, Krisztina B, D’Haens, Geert R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Leading Off
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972297/
https://www.ncbi.nlm.nih.gov/pubmed/34013959
http://dx.doi.org/10.1093/ibd/izab099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972297/
https://www.ncbi.nlm.nih.gov/pubmed/34013959
http://dx.doi.org/10.1093/ibd/izab099

Ejemplares similares